Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation

BACKGROUND: Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug Administration (FDA) has rejected many potential pharmaceutical agents due to QT prol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ranjan, Amalendu P, Mukerjee, Anindita, Helson, Lawrence, Vishwanatha, Jamboor K
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3878673/
https://ncbi.nlm.nih.gov/pubmed/24330336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-3155-11-40
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars